Table 2 Comparison of decision aid (DA) and no decision aid (noDA) regarding shared decision making, knowledge about PSA, decision concerning PSA test and distribution according to cost compensation (CC).

From: Decision aid and cost compensation influence uptake of PSA-based early detection without affecting decisional conflict: a cluster randomised trial

 

DA (n = 519)

noDA (n = 443)

p-value

Assessment of participants’ decision making n(%)

n = 489

n = 415

 < 0.001

Only by myself

193 (39)

112 (27)

Mostly by myself

103 (21)

73 (18)

By physician and myself

185 (38)

219 (53)

Mostly by physician

6 (1)

9 (2)

Only by physician

2 (0)

2 (0)

SDM-Q-9-score (0–100) for shared decision making at T0

n = 490

n = 410

 < 0.001

Median

84.4

88.9

Q25; Q75

64.4; 95.6

71.1; 100

Range

8.9–100

0–100

Participants’ knowledge (Watson-score: 1–11)

n = 495

n = 420

 < 0.001

Median

8

7

Q25; Q75

6; 9

5; 8

Range

0–11

0–11

Participants’ decision at T1 n(%)

n = 487

n = 423

 < 0.001

PSA test

350 (72)

373 (88)

No PSA test

106 (22)

32 (8)

No decision

31 (6)

18 (4)

PSA test performed until T2 n(%)

n = 457

n = 409

 < 0.001

Yes

341 (75)

361 (88)

No

114 (25)

47 (11)

Don ‘t know

2 (0)

1 (0)

Proportion of men who decided for PSA test according to CC at T1 n(%)

CC

223 (81)

246 (94)

 < 0.001

noCC

127 (60)

127 (78)

 < 0.001

  1. T0 directly after consultation, T1 two week after consultation, T2 six months after consultation, PSA prostate specific antigen, noCC without cost compensation.